Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cetuximab + Monalizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 30||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|Monalizumab||NN-8765|IPH-2201|IPH 2201|IPH2201||Monalizumab (IPH2201) is a humanized monoclonal antibody against NKG2A that blocks NKG2A ligand binding, which in turn induces cell-mediated immune response against cancer cells (PMID: 30503213, PMID: 31623687, PMID: 31308062).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||head and neck squamous cell carcinoma||not applicable||Cetuximab + Monalizumab||Phase II||Actionable||In a Phase II trial, combined Erbitux (cetuximab) and Monalizumab (IPH2201) treatment was well tolerated in patients with recurrent or metastatic head and neck squamous cell carcinoma, and resulted in a 31% (8/26) objective response rate (partial responses) and stable disease in 54% (14/26) of evaluable patients (PMID: 30503213; NCT02643550).||30503213|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02643550||Phase Ib/II||Cetuximab + Monalizumab||Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||Recruiting|